INPEFA Drug Patent Profile
Which patents cover Inpefa, and when can generic versions of Inpefa launch?
Inpefa is a drug marketed by Lexicon Pharms Inc and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in INPEFA is sotagliflozin. One supplier is listed for this compound. Additional details are available on the sotagliflozin profile page.
DrugPatentWatch® Generic Entry Outlook for Inpefa
Inpefa will be eligible for patent challenges on May 26, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 7, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for INPEFA
INPEFA is protected by three US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of INPEFA is ⤷ Start Trial.
This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INPEFA
When does loss-of-exclusivity occur for INPEFA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2807
Estimated Expiration: ⤷ Start Trial
Australia
Patent: 09270973
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 0916191
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 30931
Estimated Expiration: ⤷ Start Trial
Chile
Patent: 09001595
Estimated Expiration: ⤷ Start Trial
China
Patent: 2112483
Estimated Expiration: ⤷ Start Trial
Patent: 7629097
Estimated Expiration: ⤷ Start Trial
Colombia
Patent: 51797
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 32947
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 32947
Estimated Expiration: ⤷ Start Trial
Hong Kong
Patent: 43713
Estimated Expiration: ⤷ Start Trial
Hungary
Patent: 35400
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 0269
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 83337
Estimated Expiration: ⤷ Start Trial
Patent: 11528366
Estimated Expiration: ⤷ Start Trial
Patent: 16041701
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 11000503
Estimated Expiration: ⤷ Start Trial
New Zealand
Patent: 0184
Estimated Expiration: ⤷ Start Trial
Norway
Patent: 32947
Estimated Expiration: ⤷ Start Trial
Peru
Patent: 100260
Estimated Expiration: ⤷ Start Trial
Poland
Patent: 32947
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 32947
Estimated Expiration: ⤷ Start Trial
Russian Federation
Patent: 05543
Estimated Expiration: ⤷ Start Trial
Patent: 11105797
Estimated Expiration: ⤷ Start Trial
Singapore
Patent: 5317
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 1100175
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 1707246
Estimated Expiration: ⤷ Start Trial
Patent: 110031196
Estimated Expiration: ⤷ Start Trial
Patent: 170010069
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 56357
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 1006808
Estimated Expiration: ⤷ Start Trial
Patent: 72521
Estimated Expiration: ⤷ Start Trial
Ukraine
Patent: 6048
Estimated Expiration: ⤷ Start Trial
Uruguay
Patent: 992
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering INPEFA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 063047 | ⤷ Start Trial | |
| Austria | E496888 | ⤷ Start Trial | |
| Australia | 2007304971 | ⤷ Start Trial | |
| Brazil | PI0717156 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INPEFA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2089361 | 19C1053 | France | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | 122019000077 | Germany | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN, ODER EIN PHARMAZEUTISCH ZULAESSIGES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1363 20190426 |
| 2089361 | 2019/044 | Ireland | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | 1990043-0 | Sweden | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1363 20190430 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Investment Scenario, Market Dynamics, and Financial Trajectory for INPEFA
More… ↓
